SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs still-blinded Phase 3 REGAL trial, which needs 80 deaths to trigger final analysis; the last disclosed count was 78, leaving traders focused on the prolonged wait for confirmation and results. Bulls speculate that extended patient survival could signal GPS benefit or that results may surface around ASH, while skeptics question the delay and trial risks; the recent share decline has intensified that debate.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs Q3 adjusted EBITDA beat and stronger 2027 outlook are driving attention, with bullish traders anticipating a short-covering rally. Others are cautious that the stock may give back gains, citing the companys debt and execution concerns.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

A sharp AMP rally and surge in trading volume have drawn attention, with traders debating whether the move signals a sustained breakout or another short-lived pump-and-dump. Some connect the optimism to Flexas payments and collateral thesis and AMPs relationship with ANVL, but speculation about undisclosed news or adoption remains unconfirmed.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp selloff across AI infrastructure and neocloud stocks, amid concerns about financing costs, debt, and whether heavy data-center spending will generate durable returns. Traders are split between expecting further declines and viewing the drop as an oversold buying opportunity, with bulls arguing Nebius is financially stronger than some peers and pointing to upcoming earnings for evidence of execution.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transoceans new U.S. Gulf ultra-deepwater drillship contracts are drawing attention for adding firm backlog, with work scheduled to begin in 2027. Traders welcome the awards as evidence of demand and stronger day rates, but some remain cautious about the Valaris mergers dilution, the companys debt, and muted share-price response to positive news.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp tech-led selloff and a rebound in index futures ahead of major tech earnings, amid lingering concerns about AI valuations and spending. Traders are split on whether the bounce signals dip-buying and short covering or is a bull trap, with Black Monday crash speculation adding to the volatility debate.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is drawing attention ahead of its upcoming quarterly results, with traders positioning in options and debating whether the stock can rebound into earnings. Some expect a beat and see recent support as a buying opportunity, while others remain cautious about weak sales, production disruptions, and the risk of a post-earnings decline.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Papua New Guinea, Australia, Ghana, Suriname, Argentina, Peru, Mexico, Canada, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is drawing attention as traders look for a recovery in gold and gold-mining stocks, citing inflation and currency-debasement concerns alongside bullish technical signals. The community is broadly optimistic about a further rebound, though some point to gold-price volatility, interest-rate pressure and mining costs as risks.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

X-Energy is drawing attention amid a sharp selloff, with traders pointing to Piper Sandlers bearish coverage and the post-IPO lockup expiration as possible sources of selling pressure; some also cite weakness across nuclear stocks and the companys long commercialization timeline. Bulls view Amazons stake and future demand for nuclear power from data centers as long-term support, while others remain concerned about near-term execution and valuation.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOIs steep pullback, alongside a B. Riley price-target cut and weakness across AI/optics stocks, is driving discussion. Traders are split between concerns about dilution, funding, and further downside and dip-buyers who see AI optical-transceiver demand as intact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million.
Aethlon Medical (NASDAQ:AEMD) shares moved upwards byread more...

Biotech Bombshells and AI Power Plays: The Stocks Suddenly Turning Heads

Today’s market action is being driven by hard catalysts. Quoin Pharmaceuticals (NASDAQ:QNRX) has fresh interim clinical data; NeOnc Technologies Holdings (NASDAQ:NTHI) has moved its NEO100 story toward an FDA registration discussion; FingerMotion (NASDAQ:FNGR) is attempting a major strategic pivot toward AI infrastructure; and Solstice Advanced Materials (NASDAQ: SOLS) has replaced a transformative merger with a $500 million buyback and an independent-growth narrative. Meanwhile, Gap (NYSE: GAP) is demonstrating that a mature consumer company can still generate sharp divergence between individual brands.

Quoin Pharmaceuticals Stock Surges Friday: What's Happening?

Shares of Quoin Pharmaceuticals are rallying Friday after pre-market updates on positive trial results and a major institutional financing.read more...

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million.
Aethlon Medical (NASDAQ:AEMD) stock moved upwards byread more...

Quoin’s Netherton Data Turns Heads and Could Make QRX003 Breakout Catalyst

Quoin Pharmaceuticals (NASDAQ:QNRX) delivered the kind of interim clinical signal that can abruptly change the conversation around a small-cap biotech: its investigational QRX003 lotion produced statistically significant improvements in key measures of Netherton Syndrome in the first six patients to complete 12 weeks of treatment. The company says four of six participants, or 66.7%, achieved at least a one-grade improvement on the Investigator Global Assessment, producing a p=0.0087 result that cleared the study’s pre-specified interim alpha of 0.0215.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million.
Mobile-health Network (NASDAQ:MNDR)read more...

Quoin Pharmaceuticals Garners Buzz After FDA’s Comments On Netherton Syndrome Lead Drug

Equity

The U.S. Food and Drug Administration indicated that a single Phase 3 trial of QRX003 could be enough to support approval in the U.S.

Quoin Pharmaceuticals Gains FDA Alignment, Eyes Streamlined Path to First Netherton Syndrome Treatment

Quoin Pharmaceuticals (NASDAQ:QNRX) reported a key regulatory milestone following a constructive Type C meeting with the U.S. Food and Drug Administration (FDA), potentially accelerating the development path for its lead candidate, QRX003, in the treatment of Netherton Syndrome, a rare and underserved genetic skin disorder.

QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? 

A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

QNRX Stock Soars 300% After $104.5M Financing Through Private Placement

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$QNRX Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20 
BENZINGA 9:23 AM ET 9/23/2026  
 
Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals(QNRX) with a Buy rating and announces Price Target of $20.

$QNRX Quoin Pharmaceuticals Says FDA Granted Fast Track Designation To QRX003 For Peeling Skin Syndrome 
BENZINGA 7:33 AM ET 9/22/2026

$QNRX Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Day Trader

This guy is better than 90% of the traders on this platform!!  
      
Follow @CasualTradeer called MNDR for a 500% RUN today. Now he’s on GMEX💎 
 
Watching $QNRX & $BOXL as well..

Julian

$QNRX BTIG Initiates Quoin Pharmaceuticals at Buy With $14 Price Target 
MT NEWSWIRES 6:38 AM ET 10/12/2026

$QNRX who remember when this ran feom 8>21$ last year. hopefully another similar run comes along

Feed

News

Sentiment

Fundamentals

Info

QNRX Quoin Pharmaceuticals Ltd - ADR

Fundamentals

Latest QNRX News